Lipocine (LPCN) EBT Growth (1y) (2013 - 2025)
Lipocine (LPCN) EBT Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.48% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.60% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 88.57% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.23% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 213.87% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 530.43% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -182.24% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 96.45% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -12.04% |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -43.63% |
| Jun 30, 2025 | 28.11% |
| Mar 31, 2025 | -153.07% |
| Dec 31, 2024 | 178.11% |
| Sep 30, 2024 | 66.64% |
| Jun 30, 2024 | 13.54% |
| Mar 31, 2024 | 190.80% |
| Dec 31, 2023 | -2.34% |
| Sep 30, 2023 | -176.07% |
| Jun 30, 2023 | -34.84% |
| Mar 31, 2023 | -10.97% |
| Dec 31, 2022 | -117.66% |
| Sep 30, 2022 | 21.81% |
| Jun 30, 2022 | 61.35% |
| Mar 31, 2022 | -3.55% |
| Dec 31, 2021 | 379.83% |
| Sep 30, 2021 | 28.56% |
| Jun 30, 2021 | -6.90% |
| Mar 31, 2021 | 41.64% |
| Dec 31, 2020 | -37.03% |